Data Set for Reporting Carcinoma of the Stomach in Gastrectomy

Abstract

Context.— A standardized detailed surgical pathology report is the cornerstone of gastric cancer management. Objective.— To guide management and prognostication for patients with gastric carcinomas globally, the International Collaboration on Cancer Reporting aimed to produce an evidence-based international pathology reporting data set with a panel of globally recognized expert pathologists and clinicians. Design.— Based on published guidelines/data sets for gastric carcinomas, a working draft was developed by the chair of the expert panel of pathologists and clinicians. The draft was then circulated to the panel and discussed in a series of teleconferences and email communications until consensus was achieved. The draft data set was uploaded on the International Collaboration on Cancer Reporting Web site for public comment. The data set was reviewed in consideration of the feedback, and a final version was approved by the panel. Results.— This data set was developed for gastrectomy specimens for primary gastric carcinomas, including neuroendocrine carcinomas and mixed neuroendocrine-nonneuroendocrine neoplasms. Well-differentiated neuroendocrine tumors, nonepithelial malignancies, and secondary tumors were excluded from this data set. The final data set contains 15 core (required) elements and 8 noncore (recommended) elements. A commentary is provided for each element. Conclusions.— The International Collaboration on Cancer Reporting has published freely available, evidence-based data sets for gastric cancer reporting. Standardized reporting has been shown to improve patient care and facilitates data exchange and analysis for quality assurance, cancer epidemiology, and clinical and basic research.

A Standardized Pathology Report for Gastric Cancer: 2nd Edition

“…However, the tumor size is not used in the current staging of GC [ 8 ], and it is sometimes very difficult to measure accurately, such as in Borrmann type 4 cancer. For scattered residual tumor foci following previous treatment, it is recommended to measure the maximum diameter that includes all foci [ 12 ].…”

“…2A and B ). Although IHC for D2-40 or CD31 can be used, the prognostic differences between lymphatic and blood vessel invasion have not been sufficiently evaluated in GC [ 12 ]; therefore, we recommend using ‘lymphovascular invasion.’ However, when tumor invasion or emboli are observed in large vessels with an identifiable smooth muscle layer or elastic lamina, it is called venous invasion and can be reported as a conditional data element ( Fig. 2C ).…”

A standardized pathology report for gastric cancer: 2nd edition

“…However, the tumor size is not used in the current staging of GC [ 8 ], and it is sometimes very difficult to measure accurately, such as in Borrmann type 4 cancer. For scattered residual tumor foci following previous treatment, it is recommended to measure the maximum diameter that includes all foci [ 12 ].…”

“…2A , B). Although IHC for D2-40 or CD31 can be used, the prognostic differences between lymphatic and blood vessel invasion have not been sufficiently evaluated in GC [ 12 ]; therefore, we recommend using ‘lymphovascular invasion.’ However, when tumor invasion or emboli are observed in large vessels with an identifiable smooth muscle layer or elastic lamina, it is called venous invasion and can be reported as a conditional data element ( Fig. 2C ).…”

Editorial: Novel Molecular Targets and Treatments for Gastroesophageal Cancer

“…Among Gastric cancer, predominately adenocarcinoma, is more common than oesophageal cancer, ranking fifth for incidence and fourth for mortality globally (1). Dataset reporting of carcinoma of the stomach has also been developed by ICCR (7) to standardize the pathological reporting of gastric carcinoma. In this area, Deng et al reviewed the potential clinical value of tetraspanins in the management of gastric carcinoma.…”